|
|
|
|
|
|
|
23.03.26 - 13:06
|
Aurinia Announces Management Transition (Business Wire)
|
|
|
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced today that Kevin Tang, Aurinia's Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant to facilitate the transition.
“Aurinia thanks Peter for his many contributions to the Company over his 7-year tenure and wishes him the best in his future endeavors,” stated Mr. Tang. “Aurinia today is in an extremely strong position in no small part due to Peter's stewardship. LUPKYNIS is emerging as a standard therapy for lupus nephritis, and our lead pipeline product, aritinercept, is advancing quickly through clinical studies. I look forward to working closely with the Aurinia team on our quest to bring life-altering treatments to patients suffering from autoimmune diseases.”
Aurinia also has appointed Ryan Cole as Chief Operating Officer, Michael Hearne as Chief Financial Officer and Thomas Wei as Chief Scientific Officer. Stew Kroll and...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.02.26 - 12:03
|
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress (Business Wire)
|
|
|
Full Year 2025 LUPKYNIS Sales Grew 25%
Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 MillionROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress.
Financial Results
Total Revenue: For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million, respectively, for the same periods of 2024.
Net Product Sales: For the three and twelve months ended December 31, 2025, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $74.2 million and $271.3 million, up 29% and 25%, respectively, compared to $57.6 million and $216.2 million, respectively, for the same periods of 2024.
License, Collaboration and Royalty Reve...
|
|
|
|
|
|
|
19.02.26 - 12:06
|
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 (Business Wire)
|
|
|
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026.
Aurinia's management team will host a webcast and conference call on February 26, 2026, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-8029 / +1 201-689-8029. A replay of the webcast will be available on Aurinia's website.
About Aurinia
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
